Scarica l'app Stockscreener
2.335
13.93%
-0.385
Precedente Chiudi:
$2.72
Aprire:
$2.66
Volume 24 ore:
150.38K
Relative Volume:
3.97
Capitalizzazione di mercato:
$32.79M
Reddito:
$52.16M
Utile/perdita netta:
$-48.60M
Rapporto P/E:
-2.5659
EPS:
-0.91
Flusso di cassa netto:
$-77.48M
1 W Prestazione:
-25.45%
1M Prestazione:
-41.33%
6M Prestazione:
-72.69%
1 anno Prestazione:
-49.10%
Intervallo 1D:
$2.19
$2.75
Intervallo di 1 settimana:
$2.19
$3.25
Portata 52W:
$2.19
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
Nome
Hookipa Pharma Inc
Settore
Industria
Telefono
0114318906360
Indirizzo
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Confronta HOOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| HOOK | 2.36 | 32.79M | 52.16M | -48.60M | -77.48M | -0.91 |
| VRTX | 448.89 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.01 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.51 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.01 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-11-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-03 | Iniziato | Truist | Buy |
| 2020-10-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-19 | Ripresa | H.C. Wainwright | Buy |
| 2019-09-27 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-13 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Hookipa Pharma Inc Borsa (HOOK) Ultime notizie
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com UK
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartz
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - Quantisnow
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
Hookipa Pharma Inc Azioni (HOOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):